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Abstract
Cancer subtype classification and survival prediction both relate directly to patients’ specific treatment plans, making them
fundamental medical issues. Although the two factors are interrelated learning problems, most studies tackle each separately.
In this paper, expression levels of genes are used for both cancer subtype classification and survival prediction. We considered
350 diffuse large B-cell lymphoma (DLBCL) subjects, taken from four groups of patients (activated B-cell-like subtype dead,
activated B-cell-like subtype alive, germinal center B-cell-like subtype dead, and germinal center B-cell-like subtype alive). As
classification features, we used 11,271 gene expression levels of each subject. The features were first ranked by mRMR
(Maximum Relevance Minimum Redundancy) principle and further selected by IFS (Incremental Feature Selection) procedure.
Thirty-five gene signatures were selected after the IFS procedure, and the patients were divided into the above mentioned
four groups. These four groups were combined in different ways for subtype prediction and survival prediction, specifically,
the activated versus the germinal center and the alive versus the dead. Subtype prediction accuracy of the 35-gene signature
was 98.6%. We calculated cumulative survival time of high-risk group and low-risk groups by the Kaplan-Meier method. The
log-rank test p-value was 5.98e-08. Our methodology provides a way to study subtype classification and survival prediction
simultaneously. Our results suggest that for some diseases, especially cancer, subtype classification may be used to predict
survival, and, conversely, survival prediction features may shed light on subtype features.
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Introduction
As the most common subtype of non-Hodgkin lymphomas
(NHL), diffuse large B-cell lymphoma (DLBCL) accounts for 30 to
40 percent of lymphoid neoplasm [1]. Diffuse large B-cell
lymphoma is an aggressive, fast-growing lymphoma that can arise
in lymph nodes or outside of the lymphatic system (e.g., in the
gastrointestinal tract, testes, thyroid, or skin). Currently, diagnosis
and classification of lymphoma are based on histological
recognition of tumor cells complemented by immunophenotyping
[2,3]. The heterogeneous clinical course and different treatment
responses within the same diagnostic category, however, suggest
that current diagnostic methods should be improved [4].
Identifying patterns of gene expression can foster understanding
of the molecular mechanisms of tumorigenesis and allow for the
selection of risk-adjusted treatments. Two major subtypes of
DLBCL are identified by their genetic activity [5,6]: activated B-
cell-like (ABC) subtype and germinal center B-cell-like (GCB)
subtype. We found in the literature several studies of gene
expression profiles in DLBCL patients, with some studies focusing
on disease subtypes classification [7,8] and others on survival
prediction [9]. As it is known that the GCB subtype has a better
prognosis than ABC subtype [5] which suggest that the subtype of
DLBCL and survival are intertwined, there should exist a common
gene expression signature not only for subtype classification but
also for survival prediction.
In this study, the gene expression profiles of 350 DLBCL
patients were analyzed. We took 350 samples from four groups
(ABC dead, ABC alive, GCB dead, and GCB alive), and assuming
the group identity of each test sample was unknown, assigned each
to one of the four groups during leave-one-out cross-validation.
The features that can best discriminate the four groups of patients
were ranked by the mRMR (Maximum Relevance & Minimum
Redundancy) [10] principle. Then we applied the IFS (Incremen-
tal Feature Selection) procedure to select an optimized feature set.
During IFS procedure, each test sample was predicted to fall into
one of the four groups using Nearest Neighbor Algorithm (NNA).
As a result, 35 features were chosen. This formed a unified gene
signature for both subtype classification and survival prediction in
diffuse large B-cell lymphomas, by first separating the subjects into
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prediction. The subtype prediction accuracy of the 35-gene
signature was 98.6%, as evaluated by leave-one-out cross-
validation. The predicted high-risk and low-risk patients had
significant different overall survival level and the log-rank test p-
value was 5.98e-08.
Methods
Dataset
The data used in this work were from a lymphoma/leukemia
molecular profiling project [11] that included the gene expression
profiles and clinical data of 414 patients with newly diagnosed
diffuse large-B-cell lymphoma. The data are publicly available at
GEO http://www.ncbi.nlm.nih.gov/geo under accession number
GSE10846. We excluded from our study patients with unclassified
diagnosis. There remained 350 patients, including 73 ABC alive
samples, 94 ABC dead samples, 134 GCB alive samples, and 49
GCB dead samples. After averaging the duplicate probes to gene,
filtering the low intensity genes and quantile normalization, we
obtained the expression profiles of 11,271 genes in 350 DLBCL
patients.
Minimum-Redundancy-Maximum-Relevance (mRMR)
feature selection
Minimum-Redundancy-Maximum-Relevance (mRMR) [10] is
a widely used method for feature selection. The goal of mRMR is
to select the feature subset that can best characterize the statistical
property of a target classification variable, with the constraint that
these features are mutually as dissimilar to each other as possible,
but marginally as similar to the classification variable as possible.
The feature that has maximum relevance with the target
variable and minimum redundancy within the features is defined
as a ‘‘good’’ feature. Mutual information (MI) is used to describe
both relevance and redundancy:
I(x,y)~
ð ð
p(x,y)log
p(x,y)
p(x)p(y)
dxdy ð1Þ
where x and y are vectors; p(x,y) is the joint probabilistic density;
p(x) and p(y) are the marginal probabilistic densities.
The whole vector set is defined as V, The selected vector set
with m vectors is defined as Vs, and the to-be-selected vector set
with n vectors is defined as Vt. Relevance D of a feature f in Vt
can be calculated by Equation (2):
D~I(f,c) ð2Þ
Here c is a classification variable.
Redundancy R of a feature f in Vt with all the features in Vs
can be calculated by Equation (3):
R~
1
m
X
fi[Vs
I(f,fi) ð3Þ
mRMR function maximize relevance and minimize redundancy
by integrating Equation (2) and Equation (3):
max
fj[Vt
I(fj,c){
1
m
X
fi[Vs
I(fj,fi)
2
4
3
5(j~1,2,:::,n) ð4Þ
After the pre-evaluation procedure, a feature set S is provided:
S~ f1
0
,f2
0
,:::,fh
0
,:::,fN
0 hi
ð5Þ
The feature index reflects the evaluations for feature. The feature
that fits the Equation (4) better will be added to the set S earlier.
For example, If a,b, fa is considered to be better than fb.
Prediction model
With the features selected by mRMR, we used Nearest
Neighbor Algorithm (NNA) [12] to classify the samples into the
above mentioned categories. NNA predicts a new sample into
categories by comparing the features of this sample with the
features of those that have known categories. The distance
between two vectors px and py is defined as [13,14,15]:
D(px,py)~1{
px:py
DDpxDD:DDpyDD
ð6Þ
where px:py is the inner product of px and py, and DDpDD is the
module of vector p. px and py are considered to be more similar if
D(px,py) is smaller.
NNA chooses to classify the new pattern pt into the class of its
nearest neighbor which has the smallest D(pn,pt). That is:
D(pn,pt)~minfD(p1,pt),D(p2,pt),:::,D(pz,pt),:::,D(pN,pt)g
(z=t)
ð7Þ
where N represents the number of training samples.
Leave-one-out cross-validation method
Leave-one-out cross-validation is an effective and objective way
to evaluate prediction performance [14,15,16]. Each sample in the
data set is knocked out in turn and tested by the predictor trained
by the other samples remaining in the data set. During this
process, each sample is used not only for the training but also for
the testing.
Evaluation of prediction
Each sample was predicted into one of the groups (ABC dead,
ABC alive, GCB dead, or GCB alive), at first. Then the four
groups were merged into two classes in two different ways. In
subtype classification model, the two classes were activated B-cell-
like subtype and germinal center B-cell-like subtype. The predicted
ABC subtype samples included the predicted ABC dead and ABC
alive samples. The predicted GCB subtype samples included the
predicted GCB dead and GCB alive samples. In survival
prediction model, the two classes were high-risk group and low-
risk group. The predicted high-risk samples included the predicted
ABC dead and GCB dead samples. The predicted GCB subtype
samples included the predicted ABC alive and GCB alive samples.
To evaluate the performance of subtype classification model,
the following equation is used:
Qsubtype~
TABCzTGCB
NABCzNGCB
ð8Þ
where Qsubtype is the overall success rate for subtype prediction.
TABC represents the number of corrected predictions for ABC
subtype samples, NABC the number of total ABC subtype samples
investigated, and so forth.
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samples was calculated by the Kaplan-Meier method [17] and
analyzed by the log-rank test [18]. The log-rank test p-value was
used to evaluate the performance of survival prediction model.
Statistical analyses were performed by the open-source R software,
version 2.10.0 (www.r-project.org).
Incremental Feature Selection (IFS)
mRMR can only provide a list of features by sorting the features
according to their importance to the prediction, but it is still
unknown how many fore features in the list should be selected.
The best fore features are selected by testing all possible top
feature sets and choosing the feature set that can achieve the best
prediction accuracy or smallest log rank test p-value. The possible
feature subset Si can be expressed using the following equation:
Si~ff1,f2,:::,fig(1ƒiƒN) ð9Þ
The initial feature subset is S1~ff1g, and the last feature subset is
SN~ff1,f2,:::,fNg which includes all the features. The leave-one-
out test is used to obtain the accurate prediction accuracies of all
the feature subsets. The one that can achieve the highest
prediction accuracy or smallest log rank test p-value is considered
to be the optimized feature set selected by Incremental Feature
Selection (IFS) [14,15,19]. We can plot a curve, called an IFS
curve, with the number of features i as its x-axis and the accurate
rate or 2log10 of the log rank test p-value as its y-axis.
Results
mRMR results
Using the mRMR program downloaded from http://penglab.
janelia.org/proj/mRMR/, genome-wide 11,271 genes were ranked
and the first 500 genes were chosen as potential candidates to
discriminate the four groups of patients (ABC dead, ABC alive, GCB
dead, and GCB alive). These 500 features are as dissimilar to each
other as possible, but as similar to the classification variable as possible.
IFS results
In the IFS procedure, we built 500 feature sets based on the ordered
feature set S obtained in the mRMR ste p .A c c o r d i n g l y ,5 0 0p r e d i c t i o n
models were constructed and tested as described in the Method
section. Figure 1 shows the IFS curve for (A) subtype classification
model and (B) survival prediction model. In the IFS procedure of
subtype classification model, the predicted ABC dead and ABC alive
samples were combined as predicted ABC subtype samples; the
predicted GCB dead and GCB alive samples were combined as the
predicted GCB subtype samples. In the IFS procedure of survival
prediction model, the predicted ABC dead and GCB dead samples
were merged as high-risk samples, and the predicted ABC alive and
GCB alive samples were merged as low-risk samples.
In Figure 1A, the peak overall accuracy was 1 when the feature
number was 214. However, the overall accuracy had already
achieved 0.98 when about 30 features were used. The accuracies
only had slight undulation when more features were used. In
Figure 1B, the smallest log rank test p-value was 1e- 8.67 when
182 features were selected. The optimal feature set for subtype
classification model and survival prediction model were different,
but the fore features were the same.
Choosing the same feature set for both subtype
classification model and survival prediction model
Although the optimal feature sets for subtype classification
model and survival prediction model were not synchronous, we
did find a good balance of features for both subtype classification
model and survival prediction model, as shown in Figure 2. Since
subtype classification accuracies increased little when the feature
size was larger than 30, and some local minimal p-values were
achieved between feature size of 30 and 50, a good, balanced
feature set could be chosen with size larger than 30 and less than
50. We investigated the relationship between subtype classification
accuracies and log rank p-values by restricting the number of
features to less than 100. As shown in Figure 2, the size of a
proper feature set for both models should be at the top right corner
of the plot, indicating both high subtype classification accuracy
and small log rank p-value, and it is shown as 35. The subtype
prediction accuracy is shown as 98.6%, and log rank p-value is
shown as 5.98e-08 (1e-7.22) at the feature set of 35. The unified
35-gene signature for both subtype classification and survival
prediction in diffuse large-B-cell lymphomas are given in Table
S1. The features were sorted according to their importance to the
prediction. Figure 3 shows the hierarchical clustering heatmap of
patient samples based on expression profiles of the 35-gene
signature. Each row represents a signature gene and each column
Figure 1. The IFS curves for subtype classification model and survival prediction model. (A) The IFS curve for subtype classification
model. The peak overall accuracy was 1 when feature number was 214. However, the overall accuracy had already achieved 0.98 when about 30
features were used. The accuracies only had slight undulation when more features were used. (B) The IFS curve for survival prediction model. The
smallest log rank test p-value was 1e- 8.67 when feature number was 182. Local p-values can already reach low when feature number was around 30
to 50. When the optimized 35 features were used the subtype prediction accuracy was 98.6% and the log-rank test p-value was 1e-7.22.
doi:10.1371/journal.pone.0012726.g001
Figure 2. The relationship of subtype classification accuracies
and log rank p-values. The x-axis is subtype classification accuracy
and the y-axis is 2log10 of the log rank test p-value. The number of
features was restricted to be less than 100 and written on the dot. The
number of optimized feature set for both models was 35 which have
high subtype classification accuracy and small log rank p-value.
doi:10.1371/journal.pone.0012726.g002
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PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12726represents a patient sample. The survival and subtype status for
each patient are shown with two bars. Black survival bar
represents dead, grey survival bar represents alive; red subtype
bar stands for ABC subtype, blue subtype bar stands for GCB
subtype. The 35-gene signature clearly separated the ABC subtype
patients from GCB subtype ones. The dead patients and alive ones
were also located at different clusters. Figure 4 shows the
Kaplan–Meier curve of the predicted high-risk and low-risk
patients using the 35-gene signature. The predicted high-risk and
low-risk patients had significant different overall survival level and
the log-rank test p-value was 5.98e-08.
Comparison of our signature with reported subtype
genes and survival genes
We compared our 35-gene signature with reported subtype
genes and survival genes. From SignatureDB [20] (http://
lymphochip.nih.gov/signaturedb/), we downloaded 16 subtype
gene signatures [21,22,23] and 7 survival gene signatures [11,22].
Figure 3. The hierarchical clustering heatmap of patient samples based on expression profiles of the 35-gene signature. Each row
represents a signature gene and each column represents a patient sample. The survival and subtype status for each patient are shown with two bars.
Black survival bar represents dead, grey survival bar represents alive; red subtype bar stands for ABC subtype, blue subtype bar stands for GCB
subtype. The 35-gene signature clearly separated the ABC subtype patients from GCB subtype ones. The dead patients and alive ones were also
located at different clusters.
doi:10.1371/journal.pone.0012726.g003
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survival gene signatures. Figure 5 shows the overlap of our 35-
gene signature with reported subtype genes and survival genes.
Detailed information of each gene in our signature can be found in
Table S1. It can be seen from Figure 5 that 33 genes from our
35-gene signature are reported to be either subtype genes or
survival genes. There are two genes, NIPA2 and IFRD2, which
are not reported as subtype genes or survival genes in
SignatureDB. NIPA2 is a selective magnesium transporter [24].
It has been reported that Nipa2 is related with mammary
tumorigenesis in mice [25]. IFRD2, interferon-related develop-
mental regulator 2, is a Myc target gene involved in lymphoma-
genesis [26].
Discussion
The biological roles of the 35-gene signature
KEGG enrichment of the 35-gene signature using GATHER
[27] (Table S2) reveals that the signature genes are related to
focal adhesion, cell cycle and Wnt signaling pathway. The
enriched KEGG pathways have a close relationship with cancer.
LMO2, MYBL1, BCL6, LRMP, and CCND2 in our 35
signature genes were also reported in Lossos’s 36 genes, which
predicted survival in diffuse large-B-cell lymphoma [9]. LMO2,
ranking second in our signature list, was considered the strongest
indicator in Lossos’s six-gene signature [9] for survival prediction.
MYBL1, ranking third in our list, was also reported in Alizadeh’s
study of DLBCL subtype classification [6]. According to the
mRMR feature list, BCL6 ranked 12th (Table S1) and BCL2
ranked 250th (data not shown). GCB subtype is accompanied with
a chromosomal translocation involving gene BCL2. The expres-
sion of BCL6 may strongly predict survival in patients with diffuse
large B-cell lymphoma [28]. CCND2 ranking 35 on our signature
list was reported to be the target of BCL6 [9,29].
A number of other genes ranking high in our 35-gene signature
list are functionally important for tumorigenesis. BATF is a basic
leucine zipper transcription factor that belongs to AP-1 super
family. Stat3 modulates AP-1 activity through the induction of
Figure 4. The Kaplan–Meier curve of predicted high-risk and low-risk patients using the 35-gene signature. The log-rank test p-value
comparing the overall survival of predicted high-risk and low-risk patients is 5.98e-08.
doi:10.1371/journal.pone.0012726.g004
Figure 5. The overlap of our 35-gene signature with reported
subtype genes and survival genes. 33 genes from our 35-gene
signature are reported to be either subtype genes or survival genes.
doi:10.1371/journal.pone.0012726.g005
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proliferation, survival and differentiation [30]. It was reported that
in M1 mouse myeloid leukemia cells, forced expression of BATF
resulted in a reduced rate of cellular growth [30]. In low grade
fibromyxoid sarcoma, a chromosomal aberration involving
CREB3L2 was found [31,32]. In Cancer Gene Census (http://
www.sanger.ac.uk/genetics/CGP/Census/), CREB3L2 is record-
ed as a cancer gene of fibromyxoid sarcoma. Histone deacetylase 1
(HDAC1) is responsible for the deacetylation of lysine residues on
the N-terminal part of the core histones [33,34]. It interacts with
tumor-suppressor protein of retinoblastoma [35]. Histone deace-
tylases play an important role in cell growth arrest, differentiation,
and death, generating substantial interest in HDAC inhibitors as
possible antineoplastic agents [36–39]. PTK2 is a focal adhesion-
associated protein kinase implicated in signaling pathways
involved in cell motility, proliferation, and apoptosis [40,41]. It
is required for prostate cancer cell motility [42]. PIM2 is a proto-
oncogene [43] that acts as a serine/threonine protein kinase. It
can prevent apoptosis and to promote cell survival [44,45,46].
The relationship of subtype classification model and
survival prediction model
In DLBCL studies, there are two major tasks: subtype
classification and survival prediction. Furthermore, they are
interrelated (e.g., GCB subtype has a better prognosis than ABC
subtype [5]). Knowledge about subtype classification can improve
performance on survival prediction, and vice versa. To mutually
improve the subtype classification and survival prediction models
with the aid of the other, first we divided the samples into four
groups and then merged the four groups into two classes in two
different ways. A balance of these two models was achieved with
the 35-gene signature. The 35-gene signature proved to be useful
in both subtype classification and survival prediction of diffuse
large-B-cell lymphomas. Our methodology provides a way to study
subtype classification and survival prediction simultaneously. Our
results suggest that for some diseases, especially cancer, subtype
classification may be used to predict survival, and, conversely,
survival prediction features may shed light on subtype features.
Supporting Information
Table S1 The 35 genes in our signature
Found at: doi:10.1371/journal.pone.0012726.s001 (0.03 MB
XLS)
Table S2 KEGG enrichment of the 35 genes in our signature
using GATHER
Found at: doi:10.1371/journal.pone.0012726.s002 (0.02 MB
XLS)
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